Suzanah C. Boyd

Sydney, NSW 2065, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Analytical Performance of the Avida Duo Assay for Simultaneous Mutation and Methylation Profiling in Circulating Cell-Free DNA.

Analytical Performance of the Avida Duo Assay for Simultaneous Mutation and Methylation Profiling in Circulating Cell-Free DNA.

Journal: Cancers
Published: May 23, 2026

Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Correction: Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Journal: Oncogenesis
Published: April 10, 2026

Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment.

Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment.

Journal: Molecular cancer
Published: October 11, 2024

Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases.

Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases.

Journal: Multiple sclerosis and related disorders
Published: August 28, 2019

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.

Journal: Oncogenesis
Published: January 17, 2018

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing.

Journal: Biomarker research
Published: March 14, 2017

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Journal: Oncotarget
Published: August 03, 2015

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 06, 2014

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 28, 2014

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

Journal: The Journal of investigative dermatology
Published: March 03, 2013

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.

Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion.

Journal: The Journal of investigative dermatology
Published: November 30, 2012

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.

Journal: Oncogene
Published: May 16, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026